Mutations at codon 974 of the DPYD gene are a rare event

British Journal of Cancer

Volumn 75, Issue 2, 1997, Pages 178-179

  Ridge, S A ^a   Brown, O ^a   McMurrough, J ^a   Fernandez Salguero, P ^b   Evans, W E ^c   Gonzalez, F J ^b   McLeod, H L ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

5 fluorouracil; Dihydropyrimidine dehydrogenase; Pyrimidine metabolism; Thymine uraciluria

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL;

ARTICLE; CANCER PATIENT; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; MAJOR CLINICAL STUDY; MUTATION RATE; PRIORITY JOURNAL; PYRIMIDINE METABOLISM;

EID: 0031016021     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.29     Document Type: Article

References (13)

1. Albin N, Johnson MR, Shahinian H, Wang K and Diasio RB (1995) Initial characterisation of the molecular defect in human dihydropyrimidine dehydrogenase deficiency. Proc Am Assoc Cancer Res 36: 211
2. Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N, Schneider M, Demard F and Milano G (1994) Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12: 2248-2253
3. Gonzalez FJ and Fernandez-Sulguero P (1995) Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency. Trends Pharmacol Sci 16: 325-327
4. Harris BE, Carpenter JT and Diasio RB (1991) Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. Cancer 68: 499-501
5. Houyau P, Gay C, Chatelut E Canal P, Roche H and Milano G (1993) Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. J Natl Cancer Inst 85: 1602-1603
6. Lu Z, Zhang R and Diasio RB (1993) Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53: 5433-5438
7. McLeod HL, Lin JS, Scott EP, PUI CH and Evans WE (1994) Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 55: 15-20
8. McMurrough J and McLeod HL (1996) Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol 41: 425-427
9. Meinsma R, Fernandez-Salguero P, Van Kuilenburg ABP, Van Gennip AH and Gonzalez FJ (1995) Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uraciluria. DNA Cell Biol 14: 1-6
10. Milano G and Etienne MC (1994) Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy. Pharmacogenetics 4: 301-306
11. Naguib FNM, EL Kouni MH and CHA S (1985) Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45: 5405-5412
12. Takimoto CH, Lu ZH, Zhang R, Liang MD, Larson LV, Cantilena LR, Grem JL, Allegra CJ, Diasio RB and Chu E (1996) Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 2: 477-481
13. Wei X, McLeod HL, McMurrough J, Gonzalez FJ and Fernandez-Salguero P (1996) Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 98: 610-615